10x Genomics (NASDAQ: TXG) reported Q1 EPS of ($0.11), $0.16 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $105.8 million versus the consensus estimate of $102.51 million.

Recent Highlights

• Revenue was $105.8 million for the first quarter, representing a 47% increase over the corresponding period of 2020
• Launched Single Cell Gene Expression with CellPlex and Chromium Single Cell Gene Expression Low Throughput Kits to increase access to and affordability of single cell analysis and enable single cell for all
• Showcased new products and capabilities across three product platforms, Chromium Single Cell, Visium Spatial and In Situ Analysis, and announced the acquisition of Tetramer Shop at the first ever Xperience event in February

"We had a solid start to the year highlighted by strong growth across the business and the incredible response to the innovation revealed at our inaugural Xperience event," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "The 10x team is focused on product innovation and committed to delivering a great experience for our customers as we look to drive the Century of Biology."

GUIDANCE:

10x Genomics sees FY2021 revenue of $480-500 million, versus the consensus of $494.98 million.

• 10x Genomics is maintaining full year 2021 revenue guidance of $480 million to $500 million, representing 61% to 67% growth over full year 2020 revenue.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.